CLINICAL STUDY
Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure
Takayoshi Tsutamoto, MDa,
Atsuyuki Wada, MDa,
Keiko Maeda, MDa,
Naoko Mabuchi, MDa,
Masaru Hayashi, MDa,
Takashi Tsutsui, MDa,
Masato Ohnishi, MDa,
Masahide Sawaki, MDa,
Masanori Fujii, MDa,
Takehiro Matsumoto, MDa,
Toshiki Matsui, MDa and
Masahiko Kinoshita, MDa
a First Department of Internal Medicine, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Japan
Manuscript received June 1, 2000;
revised manuscript received November 14, 2000,
accepted December 15, 2000.
Reprint requests and correspondence: Dr. Takayoshi Tsutamoto, First Department of Internal Medicine, Shiga University of Medical Science, Tsukinowa, Seta, Otsu 520-2192, Japan
tutamoto{at}belle.shiga-med.ac.jp
 |
Abstract
|
|---|
OBJECTIVES
We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF).
BACKGROUND
Aldosterone (ALD) promotes collagen synthesis and structural remodeling of the heart. Spironolactone, an ALD receptor antagonist, is reported to reduce mortality in patients with CHF, but its influence on left ventricular remodeling has not been clarified.
METHODS
Thirty-seven patients with mild-to-moderate nonischemic CHF were randomly divided into two groups that received treatment with spironolactone (n = 20) or placebo (n = 17). We measured left ventricular volume and mass before treatment and after four months of treatment. We also measured the plasma levels of neurohumoral factors, such as atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), as well as plasma procollagen type III aminoterminal peptide (PIIINP), a marker of myocardial fibrosis.
RESULTS
Left ventricular volume and mass were significantly decreased and ejection fraction was significantly increased in the spironolactone group, while there were no changes in the placebo group. Plasma levels of ANP, BNP and PIIINP were significantly decreased after spironolactone treatment, but were unchanged in the placebo group. There was a significant positive correlation between the changes of PIIINP and changes of the left ventricular volume index (r = 0.45, p = 0.045) as well as the left ventricular mass index (r = 0.65, p = 0.0019) with spironolactone treatment.
CONCLUSIONS
These findings indicate that four months of treatment with spironolactone improved the left ventricular volume and mass, as well as decreased plasma level of BNP, a biochemical marker of prognosis and/or ventricular hypertrophy, suggesting that endogenous aldosterone has an important role in the process of left ventricular remodeling in nonischemic patients with CHF.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | ANP | = atrial natriuretic peptide | | ALD | = aldosterone | | BNP | = brain natriuretic peptide | | CHF | = congestive heart failure | | EDTA | = ethylenediaminetetraacetic acid | | LVEF | = left ventricular ejection fraction | | NYHA | = New York Heart Association | | PARC | = plasma active renin concentration | | PIIINP | = procollagen type III aminoterminal peptide | | RALES | = Randomized Aldactone Evaluation Study |
|
Despite the outstanding success achieved with angiotensin-converting enzyme (ACE) inhibitors in the treatment of congestive heart failure (CHF), the mortality rate remains relatively high; this high mortality rate is partly due to the aldosterone (ALD) escape phenomenon in patients being treated with ACE inhibitors (1–4). Recently, spironolactone was shown to reduce the mortality of patients with CHF who had already received ACE inhibitors, digitalis and diuretics. In the Randomized Aldactone Evaluation Study (RALES) (3,5), both sudden death and death from CHF were significantly reduced by spironolactone therapy. However, despite the great impact of these findings, the mechanism by which spironolactone improves mortality remains to be fully elucidated.
Aldosterone has both myocardial and renal effects that may have profound implications for left ventricular remodeling (6). A significant association has been found between plasma ALD and left ventricular mass in patients with hypertension as well as in a population-based sample, suggesting that ALD may be important in the modulation of cardiac structure (7–9). Recently, it was reported that the mineralocorticoid receptor, which mediates the action of ALD, is expressed in cardiomyocytes, endothelial cells and fibroblasts in the human heart (10–12). Aldosterone is secreted from the adrenal glands, and has been shown to stimulate cardiac collagen synthesis and fibroblast proliferation via activation of local mineralocorticoid receptors or an unexplained indirect mechanism (13–16).
Plasma levels of cardiac natriuretic peptides such as atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are increased in patients with CHF and are useful prognostic predictors, especially BNP (17–20) which is a ventricular hormone (21). The usefulness of plasma BNP is partly due to the fact that high BNP levels are significantly correlated with hemodynamic abnormalities of the left ventricular ejection fraction (LVEF) and left ventricular end-diastolic pressure (21,22). Treatment of CHF based on the plasma aminoterminal BNP level was recently reported to reduce cardiovascular events (23).
In the present study, we evaluated left ventricular volume and mass, as well as plasma levels of neurohumoral factors, such as ANP and BNP, before and after four months of treatment with spironolactone or placebo.
|
Methods
|
|---|
Patients.
We studied 37 patients with stable symptomatic CHF (New York Heart Association [NYHA] functional class II or III) and LVEF <45%. There were 29 men and eight women (mean age, 64 years). The cause of heart failure was dilated cardiomyopathy in 28 patients, hypertensive heart disease in six patients and valvular heart disease in three patients. Patients were excluded if they had coronary artery disease, renal failure, hyperkalemia or liver dysfunction. Informed consent was obtained from all patients before participation in the study, and the protocol was approved by the Human Investigations Committee of our institution. Twenty-six patients were in NYHA functional class II and 11 patients were in class III. On enrollment in the study, 24 patients were being treated with diuretics, 27 with ACE inhibitors, 27 with digitalis, 14 with beta-blockers, and three with angiotensin II type-1 receptor blockers. Most of these drugs had been administered for >3 months.
Study protocol.
This was a prospective randomized study. All of the patients were in a stable condition for at least three months before enrollment. The 37 patients with mild-to-moderate symptomatic left ventricular dysfunction were randomly divided into two groups that received treatment with spironolactone (n = 20) or placebo (n = 17). The dose of spironolactone was set at 25 mg once daily.
To measure the plasma levels of neurohumoral factors and procollagen type III aminoterminal peptide (PIIINP), blood samples were collected from an antecubital vein following supine rest for at least 30 min before and after four months of treatment with spironolactone or placebo. The samples were collected 3 h after the morning dose of medications, such as digitalis and diuretics, but before the administration of spironolactone or placebo. When four months of treatment had been completed, blood samples were also collected 3 h after the morning dose of other medications, including digitalis and diuretics, but without spironolactone or placebo being administered. M-mode echocardiography was also performed with two-dimensional monitoring using a Sonolayer phased-array sector scanner (model SSH-160A, Toshiba Co., Tokyo, Japan) in a blinded fashion before and after four months of treatment with spironolactone or placebo. Left ventricular volumes were calculated using Teichholtz’s formula, and the LVEF was determined. Left ventricular mass was calculated using previously reported method (24).
Measurement of neurohumoral factors and PIIINP.
Blood for measurement of the plasma levels of ANP, BNP and endothelin-1 was transferred to a chilled tube containing ethylenediaminetetraacetic acid (EDTA) (1 mg/ml) and aprotinin (500 kallikrein inactivator U/ml), and then was centrifuged at 3,000 rpm for 15 min at 4°C. Thus, the plasma obtained was stored at –30°C until assay. Plasma ANP and BNP concentrations were measured with a specific immunoradiometric assay for alpha-human ANP and human BNP, respectively, using a commercial kit (Shionogi, Osaka, Japan), as previously reported (19). The plasma endothelin-1 level was determined using an antibody against synthetic endothelin-1 (Peninsula Laboratories, Inc., Belmont, California) and 125I-labeled endothelin-1 (Amersham Japan, Tokyo, Japan), as previously reported (25).
Blood for measurement of the plasma levels of norepinephrine, plasma active renin concentration (PARC) and ALD was transferred to a chilled tube containing EDTA (1 mg/ml) and centrifuged at 3,000 rpm for 15 min at 4°C, after which the plasma thus obtained was stored at –30°C until assay. The plasma norepinephrine concentration was measured by high performance liquid chromatography, while PARC and ALD levels were measured using commercial radioimmunoassay kits. Plasma PIIINP levels were measured with a specific immunoradiometric assay using a commercial kit (CIS Bio International, Nagoya, Japan).
Statistical analysis.
All results are expressed as the mean ± SEM. Univariate analysis was performed using Student t test. Categorical data were compared against a chi-squared distribution. Linear regression analysis was used to determine the relationship between continuous variables. A p value <0.05 was regarded as significant.
|
Results
|
|---|
Clinical characteristics.
There were no differences in age, gender, NYHA functional class, etiology of heart failure, LVEF or medications on entry into the study between the spironolactone group and the placebo group (Table 1).
Comparison of hemodynamics and neurohumoral factors before and after treatment.
There were no differences in pretreatment heart rate, mean blood pressure, LVEF, left ventricular volume index, left ventricular mass index and plasma level of PIIINP between the spironolactone group and the placebo group, and also no differences of pretreatment neurohumoral factors, such as ANP, BNP, endothelin-1, norepinephrine, PARC and ALD (Table 2). In the placebo group, there were no significant changes in these variables after four months. In the spironolactone group, there were no significant changes in heart rate, mean blood pressure and body weight, but there was improvement of NYHA functional class (2.3 ± 0.1 vs. 1.9 ± 0.1, p = 0.002) after four months of treatment. There was a significant difference in changes of the left ventricular end-diastolic and end-systolic volume index and the left ventricular mass index between the two groups (Fig. 1). There was also a significant difference in changes in plasma level of ALD, BNP and PIIINP between the two groups (Fig. 2).
View this table:
[in this window]
[in a new window]
|
Table 2 Comparison of Hemodynamics and Neurohumoral Factors Before and After Treatment in 37 Patients With Congestive Heart Failure Divided Into Two Groups: Spironolactone or Placebo
|
|
View larger version (14K):
[in this window]
[in a new window]
|
Figure 1 Absolute changes from the baseline in left ventricular end-diastolic volume index (LVEDVI), left ventricular end-systolic volume index (LVESVI) and left ventricular mass index (LVMI) before and after treatment with placebo or spironolactone for four months in patients with mild-to-moderate congestive heart failure. *p < 0.05; **p < 0.01 versus placebo.
|
|
View larger version (13K):
[in this window]
[in a new window]
|
Figure 2 Absolute changes from the baseline in plasma levels of aldosterone (ALD), brain natriuretic peptide (BNP), and procollagen type III aminoterminal peptide (PIIINP) before and after treatment with placebo or spironolactone for four months in patients with mild-to-moderate congestive heart failure. *p < 0.05; **p < 0.01 versus placebo.
|
|
Relationship between left ventricular volume index, left ventricular mass index and PIIINP before and after spironolactone treatment.
There was significant positive correlation between changes of the plasma PIIINP level and changes of the left ventricular mass index (r = 0.65, p = 0.0019) (Fig. 3) or the left ventricular volume index (r = 0.45, p = 0.045) with spironolactone treatment. In contrast, there was no relationship between these parameters in the placebo group.
View larger version (21K):
[in this window]
[in a new window]
|
Figure 3 Correlation between the changes of procollagen type III aminoterminal peptide (PIIINP) and left ventricular mass index (LVMI) after four months of spironolactone treatment in 20 patients with mild-to-moderate congestive heart failure. Delta PIIINP = pretreatment value of PIIINP – the value of PIIINP after four months, delta LVMI = pretreatment value of LVMI – the value of LVMI after four months.
|
|
|
Discussion
|
|---|
We recently reported that the heart is a target organ for ALD, and that spironolactone (a mineralocorticoid receptor antagonist) inhibits the ALD extraction through the heart in patients with CHF (26). We also found a positive correlation between the transcardiac ALD extraction and the plasma level of PIIINP (26), a possible biochemical marker of myocardial fibrosis (27,28), suggesting that the increase in ALD extraction by the failing heart might stimulate myocardial collagen turnover, as occurs in vitro (29). However, to our knowledge, serial measurements of neurohumoral factors as well as the left ventricular volume and mass have never been done before and after long-term treatment with spironolactone. The present study demonstrated for the first time that four months of treatment with spironolactone could improve left ventricular volume and mass index, as well as reduce plasma levels of BNP and PIIINP in patients with nonischemic CHF. The reduction of left ventricular volume and mass may have been due to blocking the mineralocorticoid receptor, which is known to be expressed in the human heart (14,15), since blood pressure and body weight did not change after spironolactone therapy.
Plasma ANP and BNP are useful prognostic predictors in patients with CHF, especially the level of BNP (17–20) since it is a ventricular hormone (21). The plasma BNP level was reported to be correlated with hemodynamic abnormalities of the LVEF and left ventricular end-diastolic pressure (21,22) as well as left ventricular mass (30). Therefore, the decrease of plasma BNP after treatment with spironolactone was due to the decreased left ventricular filling pressure, improvement of left ventricular remodeling or both. The decrease of BNP with spironolactone therapy may have reflected improvement of left ventricular diastolic function secondary to the effects of this drug on cardiac hypertrophy and fibrosis. Treatment of CHF guided by the plasma aminoterminal BNP level has been reported to reduce cardiovascular events (23), so the decrease of BNP may be associated with a beneficial outcome as was the case in the RALES study (5).
The plasma PIIINP level may be a biochemical marker of myocardial fibrosis and/or left ventricular remodeling in patients with CHF (26–28). In our previous study (26), there was a positive correlation between the plasma PIIINP level and the left ventricular end-diastolic volume index and between the transcardiac ALD extraction and the plasma PIIINP level, suggesting an interaction between ALD extraction and left ventricular remodeling in patients with CHF. In the present study, plasma PIIINP was significantly decreased after spironolactone therapy, which was consistent with the previous study (31), and there was a significant positive correlation between the changes of PIIINP and the changes of left ventricular volume and mass with spironolactone treatment. Although the cause and effect of the relationship between the changes in PIIINP and the changes in left ventricular volume and mass remain unknown, the present study suggests that PIIINP is a useful marker of the effect of spironolactone on left ventricular remodeling.
An increase of PARC and ALD has been observed with spironolactone therapy, suggesting blockade of ALD receptors and loss of negative feedback inhibition (32). In the present study, the plasma levels of norepinephrine and endothelin-1 were not changed after spironolactone therapy, but we cannot deny the possibility that spironolactone may increase cardiac norepinephrine uptake and improve cardiac sympathetic activity in patients with CHF (32).
Study limitations.
In the present study, patients with CHF secondary to coronary artery disease were excluded, since it is difficult to evaluate left ventricular volume and mass in such patients. Therefore, further studies are needed to assess the effects of spironolactone in patients with ischemic cardiomyopathy. In addition, the small number of patients with nonischemic CHF was also a limitation of the present study. The present study employed a fixed spironolactone dose of 25 mg/d, therefore, the dose-response effect of spironolactone on left ventricular remodeling and BNP must also be evaluated.
|
Conclusions
|
|---|
Plasma levels of ANP, BNP and PIIINP were significantly decreased after four months of spironolactone treatment, but did not change in the placebo group. There was a significant positive correlation between the changes of PIIINP and the changes of left ventricular volume and mass with spironolactone therapy. These findings indicate that long-term spironolactone treatment can improve left ventricular remodeling and decrease the plasma level of BNP, a biochemical marker of prognosis and/or ventricular hypertrophy, in patients with nonischemic CHF.
|
Acknowledgments
|
|---|
We wish to thank Ms. Ikuko Sakaguchi for her excellent technical assistance.
|
Footnotes
|
|---|
Supported in part by Japanese Grants-in-Aid for Scientific Research (C).
|
References
|
|---|
1. Cleland JGF, Dargie HJ, Hodsman GP, et al. Captopril in heart failure: a double-blind controlled trial. Br Heart J. 1984;52:530–535[Abstract/Free Full Text]
2. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1965;25:219–228
3. Pitt D. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J. 1995;16(Suppl N):107–110
4. Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J. 1995;16(Suppl N):103–107
5. Randomized Aldactone Evaluation Study InvestigatorsPitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on mortality and morbidity in patients with severe heart failure. N Engl J Med. 1999;341:709–717[Abstract/Free Full Text]
6. Weber KT, Brilla C. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849–1865[Abstract/Free Full Text]
7. Duprez DA, Bauwens FR, De Buyzere ML, et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 1993;71:17A–20A[CrossRef][Medline]
8. Navarro-Lopez F, Coca A, Pare JC, de la Sierra A, Bosch X, Urbano Marquez A. Left ventricular hypertrophy in asymptomatic essential hypertension: its relationship with aldosterone and the increase in sodium-proton exchanger activity. Eur Heart J. 1993;14(Suppl J):38–41
9. Schunkert H, Hense HW, Danser J, Muscholl M, Luncher A, Riegger AJG. Association between circulating components of the renin angiotensin aldosterone system and left ventricular mass. Br Heart J. 1997;77:24–31[Abstract/Free Full Text]
10. Scoot BA, Lawrence B, Nguyen HH, Meyer WJ III. Aldosterone and dexamethasone binding in human arterial smooth muscle cells. J Hypertens. 1987;5:739–744[CrossRef][Medline]
11. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action, mineralocorticoid receptor and 11b-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995;92:175–182[Abstract/Free Full Text]
12. Zennaro MC, Farman N, Bonbalet JP, Lombes M. Tissue-specific expression of and messenger ribonucleic acid isoforms of the human mineralocorticoid receptor in normal and pathological states. J Clin Endocrinol Metab. 1997;82:1345–1352[Abstract/Free Full Text]
13. Young M, Fullerton M, Dilley R, Funder JW. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;92:2578–2583
14. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809–820[CrossRef][Medline]
15. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res. 1992;71:503–510[Abstract/Free Full Text]
16. Robert V, Silvestre JS, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension. 1995;26:971–978[Abstract/Free Full Text]
17. Gottlieb SS, Kukin MC, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 1989;13:1534–1539[Abstract]
18. Omland T, Aakvaag A, Bonarjee VVS, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996;93:1963–1969[Abstract/Free Full Text]
19. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509–516[Abstract/Free Full Text]
20. Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction: comparison with plasma angiotensin II and endothelin-1. Eur Heart J. 1999;20:1799–1807[Abstract/Free Full Text]
21. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195–203[Abstract/Free Full Text]
22. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135:825–832[CrossRef][Medline]
23. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–1130[CrossRef][Medline]
24. Committee on M-mode standardization of the American Society of EchocardiographySahn D, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a society of echocardiographic measurements. Circulation. 1978;58:1072–1083[Abstract/Free Full Text]
25. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 1994;23:1427–1433[Abstract]
26. Tsutamoto T, Wada A, Maeda K, et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:838–844[Abstract/Free Full Text]
27. Klappacher G, Franzen P, Haab D, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995;75:913–918[CrossRef][Medline]
28. Host NB, Jensen LT, Bendixen PM, Jensen SE, Koldkjaer OG, Simonsen EE. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol. 1995;76:869–873[CrossRef][Medline]
29. Robert V, Silvestre JS, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension. 1995;26:971–978[Abstract/Free Full Text]
30. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med. 1992;92:29–34[CrossRef][Medline]
31. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improve heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30–34[Abstract/Free Full Text]
32. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery diseases. Am J Cardiol. 1995;76:1259–1265[CrossRef][Medline]
This article has been cited by other articles:
|
|
|
|
 
M. J. Haykowsky, J. R. Mackey, R. B. Thompson, L. W. Jones, and D. I. Paterson
Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training
Clin. Cancer Res.,
August 1, 2009;
15(15):
4963 - 4967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Iraqi, P. Rossignol, M. Angioi, R. Fay, J. Nuee, J. M. Ketelslegers, J. Vincent, B. Pitt, and F. Zannad
Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure: Insights From the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Study
Circulation,
May 12, 2009;
119(18):
2471 - 2479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ezekowitz and F. A. McAlister
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials
Eur. Heart J.,
February 2, 2009;
30(4):
469 - 477.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Boccanelli, G. F. Mureddu, G. Cacciatore, F. Clemenza, A. Di Lenarda, A. Gavazzi, M. Porcu, R. Latini, D. Lucci, A. P. Maggioni, et al.
Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results
Eur J Heart Fail,
January 1, 2009;
11(1):
68 - 76.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Maisel, C. Mueller, K. Adams Jr., S. D. Anker, N. Aspromonte, J. G.F. Cleland, A. Cohen-Solal, U. Dahlstrom, A. DeMaria, S. Di Somma, et al.
State of the art: Using natriuretic peptide levels in clinical practice
Eur J Heart Fail,
September 1, 2008;
10(9):
824 - 839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. F. Murphy, C. O'Loughlin, M. Ledwidge, D. McCaffrey, and K. McDonald
Improvement but no cure of left ventricular systolic dysfunction in treated heart failure patients
Eur J Heart Fail,
December 1, 2007;
9(12):
1196 - 1204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure
Circulation,
July 31, 2007;
116(5):
e99 - e109.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Haykowsky, Y. Liang, D. Pechter, L. W. Jones, F. A. McAlister, and A. M. Clark
A Meta-Analysis of the Effect of Exercise Training on Left Ventricular Remodeling in Heart Failure Patients: The Benefit Depends on the Type of Training Performed
J. Am. Coll. Cardiol.,
June 19, 2007;
49(24):
2329 - 2336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Jourdain, G. Jondeau, F. Funck, P. Gueffet, A. Le Helloco, E. Donal, J. F. Aupetit, M. C. Aumont, M. Galinier, J. C. Eicher, et al.
Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure: The STARS-BNP Multicenter Study
J. Am. Coll. Cardiol.,
April 24, 2007;
49(16):
1733 - 1739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Berry, N. Murphy, G. De Vito, S. Galloway, A. Seed, C. Fisher, N. Sattar, P. Vallance, W. S. Hillis, and J. McMurray
Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker
Eur J Heart Fail,
April 1, 2007;
9(4):
429 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ohtani, M. Ohta, K. Yamamoto, T. Mano, Y. Sakata, M. Nishio, Y. Takeda, J. Yoshida, T. Miwa, M. Okamoto, et al.
Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker
Am J Physiol Regulatory Integrative Comp Physiol,
February 1, 2007;
292(2):
R946 - R954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schou, F. Gustafsson, A. Kjaer, and P. R. Hildebrandt
Long-term clinical variation of NT-proBNP in stable chronic heart failure patients
Eur. Heart J.,
January 11, 2007;
(2007)
ehl449v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schou, F. Gustafsson, P. H. Nielsen, L. H. Madsen, A. Kjaer, and P. R. Hildebrandt
Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state
Eur J Heart Fail,
January 1, 2007;
9(1):
68 - 74.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Braunschweig, A. Fahrleitner-Pammer, M. Mangiavacchi, S. Ghio, P. Fotuhi, U. C. Hoppe, and C. Linde
Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure
Eur J Heart Fail,
December 1, 2006;
8(8):
797 - 803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Birks, P. D. Tansley, J. Hardy, R. S. George, C. T. Bowles, M. Burke, N. R. Banner, A. Khaghani, and M. H. Yacoub
Left Ventricular Assist Device and Drug Therapy for the Reversal of Heart Failure
N. Engl. J. Med.,
November 2, 2006;
355(18):
1873 - 1884.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Felker, J. W. Petersen, and D. B. Mark
Natriuretic peptides in the diagnosis and management of heart failure.
Can. Med. Assoc. J.,
September 12, 2006;
175(6):
611 - 617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Lainchbury, R. W. Troughton, C. M. Frampton, T. G. Yandle, A. Hamid, M. G. Nicholls, and A. M. Richards
NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial
Eur J Heart Fail,
August 1, 2006;
8(5):
532 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G A Wright and A D Struthers
Natriuretic peptides as a prognostic marker and therapeutic target in heart failure
Heart,
February 1, 2006;
92(2):
149 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. W. Tang, A. C. Parameswaran, A. P. Maroo, and G. S. Francis
Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1623 - 1630.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Izawa, T. Murohara, K. Nagata, S. Isobe, H. Asano, T. Amano, S. Ichihara, T. Kato, S. Ohshima, Y. Murase, et al.
Mineralocorticoid Receptor Antagonism Ameliorates Left Ventricular Diastolic Dysfunction and Myocardial Fibrosis in Mildly Symptomatic Patients With Idiopathic Dilated Cardiomyopathy: A Pilot Study
Circulation,
November 8, 2005;
112(19):
2940 - 2945.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Fraccarollo, P. Galuppo, I. Schmidt, G. Ertl, and J. Bauersachs
Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction
Cardiovasc Res,
July 1, 2005;
67(1):
97 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G.A. Veliotes, A. J. Woodiwiss, D. A.J. Deftereos, D. Gray, O. Osadchii, and G. R. Norton
Aldosterone Receptor Blockade Prevents the Transition to Cardiac Pump Dysfunction Induced by {beta}-Adrenoreceptor Activation
Hypertension,
May 1, 2005;
45(5):
914 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bruins, M. R. Fokkema, J. W.P. Romer, M. J.L. DeJongste, F. P.L. van der Dijs, J. M.W. van den Ouweland, and F. A.J. Muskiet
High Intraindividual Variation of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in Patients with Stable Chronic Heart Failure
Clin. Chem.,
November 1, 2004;
50(11):
2052 - 2058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hernandez
Left ventricular hypertrophy after renal transplantation: new approach to a deadly disorder
Nephrol. Dial. Transplant.,
July 1, 2004;
19(7):
1682 - 1686.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J E Macdonald, N Kennedy, and A D Struthers
Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment
Heart,
July 1, 2004;
90(7):
765 - 770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Vasan, J. C. Evans, E. J. Benjamin, D. Levy, M. G. Larson, J. Sundstrom, J. M. Murabito, F. Sam, W. S. Colucci, and P. W. F. Wilson
Relations of Serum Aldosterone to Cardiac Structure: Gender-Related Differences in the Framingham Heart Study
Hypertension,
May 1, 2004;
43(5):
957 - 962.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Hartmann, M. Packer, A. J.S. Coats, M. B. Fowler, H. Krum, P. Mohacsi, J. L. Rouleau, M. Tendera, A. Castaigne, J. Trawinski, et al.
NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy
Eur J Heart Fail,
March 15, 2004;
6(3):
343 - 350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bettencourt
NT-proBNP and BNP: biomarkers for heart failure management
Eur J Heart Fail,
March 15, 2004;
6(3):
359 - 363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. de Denus, C. Pharand, and D. R. Williamson
Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone
Chest,
February 1, 2004;
125(2):
652 - 668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Clerico and M. Emdin
Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review
Clin. Chem.,
January 1, 2004;
50(1):
33 - 50.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Oestreicher, D. Martinez-Vasquez, J. R. Stone, L. Jonasson, W. Roubsanthisuk, K. Mukasa, and G. K. Adler
Aldosterone and Not Plasminogen Activator Inhibitor-1 Is a Critical Mediator of Early Angiotensin II/NG-Nitro-l-Arginine Methyl Ester-Induced Myocardial Injury
Circulation,
November 18, 2003;
108(20):
2517 - 2523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Fraccarollo, P. Galuppo, S. Hildemann, M. Christ, G. Ertl, and J. Bauersachs
Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction
J. Am. Coll. Cardiol.,
November 5, 2003;
42(9):
1666 - 1673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Cohn, I. S. Anand, R. Latini, S. Masson, Y.-T. Chiang, and R. Glazer
Sustained Reduction of Aldosterone in Response to the Angiotensin Receptor Blocker Valsartan in Patients With Chronic Heart Failure: Results From the Valsartan Heart Failure Trial
Circulation,
September 16, 2003;
108(11):
1306 - 1309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Hernandez and C. M. O'Connor
Sparing a little may save a lot: Lessons from the Studies of Left Ventricular Dysfunction (SOLVD)
J. Am. Coll. Cardiol.,
August 20, 2003;
42(4):
709 - 711.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Cardarelli and T. G. Lumicao Jr
B-type Natriuretic Peptide: A Review of Its Diagnostic, Prognostic, and Therapeutic Monitoring Value in Heart Failure for Primary Care Physicians
J Am Board Fam Med,
July 1, 2003;
16(4):
327 - 333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ruskoaho
Cardiac Hormones as Diagnostic Tools in Heart Failure
Endocr. Rev.,
June 1, 2003;
24(3):
341 - 356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bozkurt and D. L. Mann
Use of Biomarkers in the Management of Heart Failure: Are We There Yet?
Circulation,
March 11, 2003;
107(9):
1231 - 1233.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Effect of spironolactone on cardiacsympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy
J. Am. Coll. Cardiol.,
February 19, 2003;
41(4):
574 - 581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Rousseau, O. Gurne, D. Duprez, W. Van Mieghem, A. Robert, S. Ahn, L. Galanti, J.-M. Ketelslegers, and Belgian RALES Investigators
Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: Results from the RALES neurohormonal substudy
J. Am. Coll. Cardiol.,
November 6, 2002;
40(9):
1596 - 1601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Hausmann and N. Liel-Cohen
Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function
Nephrol. Dial. Transplant.,
November 1, 2002;
17(11):
2035 - 2036.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Spironolactone Improves Cardiac Sympathetic Nerve Activity and Symptoms in Patients with Congestive Heart Failure
J. Nucl. Med.,
October 1, 2002;
43(10):
1279 - 1285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Davies and A. Struthers
Review: The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus
Journal of Renin-Angiotensin-Aldosterone System,
September 1, 2002;
3(3):
150 - 155.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Cicoira, L. Zanolla, A. Rossi, G. Golia, L. Franceschini, G. Brighetti, P. Marino, and P. Zardini
Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure
J. Am. Coll. Cardiol.,
July 17, 2002;
40(2):
304 - 310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. Rossi, V. Di Bello, C. Ganzaroli, A. Sacchetto, M. Cesari, A. Bertini, D. Giorgi, R. Scognamiglio, M. Mariani, and A. C. Pessina
Excess ldosterone Is Associated With Alterations of Myocardial Texture in Primary Aldosteronism
Hypertension,
July 1, 2002;
40(1):
23 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sodian, M. Loebe, C. Schmitt, E. V. Potapov, H. Siniawski, J. Muller, H. Hausmann, H. R. Zurbruegg, Y. Weng, and R. Hetzer
Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems
J. Am. Coll. Cardiol.,
December 1, 2001;
38(7):
1942 - 1949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Kalra and R. Sharma
Absolute, not relative, changes are important when interpreting trial data
J. Am. Coll. Cardiol.,
December 1, 2001;
38(7):
2132 - 2132.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, et al.
Absolute, not relative, changes are important when interpreting trial data: Reply
J. Am. Coll. Cardiol.,
December 1, 2001;
38(7):
2132 - 2133.
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Methods
